Aimfinity Investment Corp. I 8-K

What Happened

• Aimfinity Investment Corp. I (AIMUF) filed a Current Report on Form 8-K on June 25, 2026 to supplement the Definitive Proxy Statement (filed March 6, 2025) for its approved business combination with Docter (approved at an extraordinary meeting on March 27, 2025).
• AIMUF disclosed two additional independent director nominees for the combined public company (PubCo): William Frank Koschak (57), who the board says qualifies as an “audit committee financial expert,” and Jonathan Bond (68). Both will serve on PubCo’s audit, compensation and nominating & corporate governance committees. The filing also updates the anticipated PubCo leadership roster (I‑Fa Chang as CEO and Chairman; Crystal Wu as CFO; Hsin‑Ming Huang as CTO; plus independent directors Kevin Vassily, Teng‑Wei Chen, Jonathan Tien, Koschak and Bond).
• The filing reported near-term commercial activity for Docter: a first product shipment to a Taiwan SECOM subsidiary (~NT$1.66 million) and a customized mmWave sensor order from Leeway Biomedical for 300 iCARE BTbed_V2 units (≈NT$2,268,000), with potential expansion to ~10,000 units (approx. USD 2.5M) if testing scales. Several hospital tenders using Docter’s mmWave tech are expected to proceed in the coming months.

Key Details

• 8‑K filed: June 25, 2026; Definitive Proxy originally filed: March 6, 2025; Business Combination approved: March 27, 2025.
• New independent nominees: William Frank Koschak (audit committee financial expert) and Jonathan Bond; both to join audit, compensation and nominating committees.
• Director compensation: each independent director to receive 20,000 PubCo Ordinary Shares annually while serving.
• Commercial orders: initial shipment ≈NT$1.66M to a Taiwan SECOM subsidiary; Leeway Biomedical order 300 units ≈NT$2,268,000 (pre‑tax) with possible expansion to ~10,000 units (~USD 2.5M); multiple hospital tenders anticipated.

Why It Matters

• Governance: Adding two experienced independent directors and naming an audit committee financial expert addresses public‑company governance and oversight needs for the combined entity, which investors often view as positive for financial reporting and controls.
• Commercial traction: Reported shipments and small‑batch orders provide early revenue and pilot opportunities for Docter’s mmWave products and hint at scalable demand (especially if government or hospital tenders convert to larger orders).
• Caution: The filing stresses these are forward‑looking expectations subject to risk — hospital projects depend on public tenders, pilot orders may not scale, and the combined company’s results may differ materially. Investors should read the Final Prospectus and related SEC filings for full risk disclosure.